Amarin Co. Plc (NASDAQ:AMRN) Shares Sold by Eversept Partners LP
Amarin Co. Plc (NASDAQ:AMRN) Shares Sold by Eversept Partners LP
Eversept Partners LP cut its stake in Amarin Co. plc (NASDAQ:AMRN – Get Rating) by 15.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,980,145 shares of the biopharmaceutical company's stock after selling 1,593,157 shares during the quarter. Amarin comprises approximately 2.4% of Eversept Partners LP's investment portfolio, making the stock its 13th biggest position. Eversept Partners LP owned about 2.26% of Amarin worth $29,545,000 at the end of the most recent reporting period.
根据Eversept Partners LP最近提交给美国证券交易委员会(SEC)的13F文件，该公司第一季度将所持Amarin Co.plc(纳斯达克代码：AMRN-GET Rating)的股份削减了15.1%。该基金在本季度出售了1,593,157股后，持有这家生物制药公司的股票8,980,145股。Amarin约占Eversept Partners LP投资组合的2.4%，使其成为其第13大头寸。截至最近一次报告期结束，Eversept Partners LP拥有Amarin约2.26%的股份，价值29,545,000美元。
A number of other hedge funds and other institutional investors have also modified their holdings of AMRN. UMB Bank N A MO purchased a new position in shares of Amarin in the 4th quarter valued at about $28,000. Winthrop Advisory Group LLC purchased a new position in shares of Amarin in the 1st quarter valued at about $34,000. Sciencast Management LP purchased a new position in shares of Amarin in the 1st quarter valued at about $51,000. Running Point Capital Advisors LLC purchased a new position in shares of Amarin in the 1st quarter valued at about $53,000. Finally, C2C Wealth Management LLC purchased a new position in shares of Amarin in the 4th quarter valued at about $75,000. 34.15% of the stock is owned by institutional investors and hedge funds.
其他一些对冲基金和其他机构投资者也调整了对amrn的持有量。UMB Bank N A MO在第四季度购买了价值约28,000美元的Amarin新股票头寸。温思罗普咨询集团有限责任公司在第一季度购买了价值约3.4万美元的Amarin新股票头寸。Sciencast Management LP在第一季度购买了新的Amarin股票头寸，价值约51,000美元。Running Point Capital Advisors LLC在第一季度购买了价值约53,000美元的Amarin新股票头寸。最后，C2C Wealth Management LLC在第四季度购买了价值约75,000美元的Amarin新股票头寸。34.15%的股票由机构投资者和对冲基金持有。
Amarin Price Performance
阿玛林的价格表现
Shares of NASDAQ:AMRN traded up $0.02 during trading on Friday, reaching $1.37. The company had a trading volume of 4,726,677 shares, compared to its average volume of 3,642,711. Amarin Co. plc has a fifty-two week low of $1.09 and a fifty-two week high of $5.52. The firm has a market capitalization of $552.40 million, a price-to-earnings ratio of -5.48 and a beta of 1.87. The stock's fifty day moving average price is $1.39 and its 200 day moving average price is $2.08.
纳斯达克：AMRN的股价在周五的交易中上涨了0.02美元，达到1.37美元。该公司成交量为4,726,677股，而其平均成交量为3,642,711股。Amarin公司股价跌至1.09美元的52周低点和5.52美元的52周高点。该公司的市值为5.524亿美元，市盈率为-5.48倍，贝塔系数为1.87。该股的50日移动均线价格为1.39美元，200日移动均线价格为2.08美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Several equities analysts have recently issued reports on AMRN shares. The Goldman Sachs Group decreased their price objective on Amarin from $1.75 to $1.50 and set a "sell" rating for the company in a research note on Tuesday, May 24th. StockNews.com raised Amarin from a "sell" rating to a "hold" rating in a research report on Wednesday, July 27th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $2.50.
几位股票分析师最近发布了有关amrn股票的报告。5月24日，高盛夫妇将Amarin的目标价从1.75美元下调至1.5美元，并在周二的一份研究报告中为该公司设定了“卖出”评级。在7月27日(周三)的一份研究报告中，StockNews.com将Amarin的评级从“卖出”上调至“持有”。两名研究分析师对该股的评级为卖出，四名分析师对该公司股票的评级为持有，一名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，该股的普遍评级为持有，平均目标价为2.50美元。
Insider Activity at Amarin
阿马林的内幕活动
In other Amarin news, Director Olsen Per Wold purchased 55,000 shares of the firm's stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average cost of $1.69 per share, for a total transaction of $92,950.00. Following the completion of the purchase, the director now directly owns 149,000 shares in the company, valued at $251,810. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.90% of the company's stock.
在阿马林的其他新闻方面，董事奥尔森在6月13日(星期一)的一笔交易中购买了55,000股该公司的股票。这些股票是以每股1.69美元的平均成本购买的，总交易额为92,950.00美元。收购完成后，董事现在直接拥有该公司149,000股，价值251,810美元。这笔收购是在提交给美国证券交易委员会的一份文件中披露的，可以通过美国证券交易委员会网站访问该文件。公司内部人士持有该公司0.90%的股份。
About Amarin
关于阿玛林
(Get Rating)
(获取评级)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Amarin Corporation plc是一家制药公司，在美国、德国、加拿大、黎巴嫩和阿拉伯联合酋长国从事心血管疾病治疗药物的开发和商业化。它的主要产品是Vascepa，一种仅限处方的omega-3脂肪酸产品，用作饮食的辅助产品，用于降低患有严重高甘油三酯血症的成年患者的甘油三酯水平。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Amarin (AMRN)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- 免费获取StockNews.com关于Amarin的研究报告(Amrn)
- MarketBeat：回顾一周9/5-9/9
- 为网络安全股创纪录的季度做准备
- 汽车市场正在缓慢复苏，这些股票可能表现优异
- DocuSign是否即将发生重大逆转？
- 石油和天然气股票：投资可再生能源的安全途径
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿马林日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Amarin和相关公司的最新新闻和分析师评级的每日简要摘要。